ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 149
- Registration Number
- NCT00634049
- Locations
- 🇺🇸
UMASS Memorial Medical Center, Worcester, Massachusetts, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Upstate Infectious Diseases Association LLP, Albany, New York, United States
Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-03-06
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 249
- Registration Number
- NCT00629642
A Study of ASP1941 in Participants With Type 2 Diabetes Mellitus
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 361
- Registration Number
- NCT00621868
A Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Stable Liver Transplantation Patients
- First Posted Date
- 2008-02-21
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 172
- Registration Number
- NCT00619398
A Study to Assess the Efficacy and Safety of Alefacept in Kidney Transplant Recipients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-18
- Last Posted Date
- 2016-02-04
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 218
- Registration Number
- NCT00617604
Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 84
- Registration Number
- NCT00608335
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸University of California Los Angeles Medical Center, Los Angeles, California, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
Study of Mycamine® in Infants and Toddlers With Fungal Infections to Evaluate Safety and Blood Levels of the Drug
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 9
- Registration Number
- NCT00607763
A Study of Safety and Pharmacokinetics of Repeated Dose of Micafungin as Antifungal Prophylaxis in Children and Adolescents Who Undergo Hematopoietic Stem Cell Transplant
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 42
- Registration Number
- NCT00606268
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2011-09-27
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 60
- Registration Number
- NCT00603356
- Locations
- 🇬🇧
The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2013-03-25
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 685
- Registration Number
- NCT00595426
© Copyright 2024. All Rights Reserved by MedPath